Aura Biosciences completes enrollment in Phase 3 CoMpass trial of bel-sar in early choroidal melanoma
PUBT · 06/01 12:01
Share
Listen to the news
- Aura Biosciences completed enrollment of 108 patients in the Phase 3 CoMpass trial of bel-sar in early choroidal melanoma.
- Topline results for the 15-month primary endpoint have not been presented; they are expected in the second half of 2027.
- The trial is designed to determine whether bel-sar can work as a frontline, vision-preserving treatment versus a sham control.
- The study is intended to support a potential regulatory filing, positioning bel-sar as a possible first approved frontline option in this setting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aura Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010800PRIMZONEFULLFEED9729005) on June 01, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved